跳至主要内容
临床试验/NCT01460641
NCT01460641已完成不适用

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

Stanford University1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
21
试验地点
1
主要终点
Tumor stage change from Computed Tomography (CT) perfusion measurement

研究概览

简要总结

A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.

详细描述

Recent advances in computed tomography (CT) technology have made CT perfusion imaging feasible for the assessment of tumor perfusion in solid tumors of the abdomen. CT perfusion has shown promising results in serving as a noninvasive method of predicting response to therapy in cancer patients. CT perfusion parameters have also been found to correlate with immunohistologic markers of angiogenesis in a number of solid tumors, suggesting a possible role for CT perfusion as a noninvasive biomarker of tumor angiogenesis. The goals of the investigators study are twofold: first, to determine the relationship between baseline CT perfusion characteristics of rectal cancers and their response to treatment, and second, to determine if perfusion CT can be used to subsequently monitor tumor response to treatment. The investigators hope to enroll those patients with locally advanced rectal cancer undergoing standard CT for pre-treatment planning, integrating CT perfusion imaging into the current abdomen/pelvis imaging protocol with close clinical and radiologic follow-up after treatment to determine response to therapy and time to disease progression.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with suspected or biopsy-proven, locally advanced rectal cancer will be eligible for enrollment.
  • Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.
  • No life expectancy restrictions.
  • ECOG and Karnofsky Performance Status will not be employed.
  • Patients with renal failure are ineligible for this study (GFR must be > 60)
  • Ability to understand and willingness to sign a written informed consent document.

排除标准

  • Patients who have undergone prior treatment for rectal cancer are ineligible for enrollment.
  • No restrictions regarding use of other investigational agents.
  • Patients with severe contrast allergy are ineligible.
  • Patients who are pregnant or are trying to become pregnant are excluded from this study.
  • Patients who are cancer survivors or HIV-positive will not be excluded.

结局指标

主要结局

Tumor stage change from Computed Tomography (CT) perfusion measurement

时间窗: 3 months

次要结局

  • Tumor perfusion as measured by perfusion CT.(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Aya Kamaya

Associate Professor of Radiology

Stanford University

研究点 (1)

Loading locations...

相似试验